The Food and Drug Administration (FDA) has approved Rezvoglar (insulin glargine-aglr), the second biosimilar product to Lantus (insulin glargline).
Rezvoglar is a long-acting human insulin analogue indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. The approval was based on data demonstrating that there were no clinically meaningful differences between the biosimilar product and the reference product.
As a biosimilar product, Rezvoglar can be used in place of Lantus; however, patients would need a prescription specifically written for Rezvoglar as the products are not considered interchangeable.
Rezvoglar is supplied as 100 Units/mL of insulin glargine in 3mL single-use prefilled pens.
Reference
Rezvoglar. Package insert. Eli Lilly and Company; 2021. Accessed December 20, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761215s000lbl.pdf.
